Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica Ltd Announces Submission of Investigational New Drug Application for Novel Oncology Drug Candidate Bal0891

11/16/2021 | 01:15am EST

Basilea Pharmaceutica Ltd. announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), to start clinical studies with the company?s novel drug candidate BAL0891 in cancer therapy. BAL0891 is a potential first-in-class small-molecule kinase inhibitor. If the IND is granted, Basilea plans to initiate a phase 1 study in patients with advanced solid tumors in the first quarter of 2022. The two oncology drug candidates already in clinical development are derazantinib, an inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases, which is currently in clinical studies for the treatment of bile duct (iCCA), urothelial and gastric cancers (the FIDES studies), and lisavanbulin, a tumor checkpoint controller, currently in clinical studies with patients with glioblastoma, the most aggressive primary brain cancer.


ę S&P Capital IQ 2021
All news about BASILEA PHARMACEUTICA AG
01/13Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection
MT
01/13Basilea announces approval of antifungal Cresemba« (isavuconazole) for invasive aspergi..
AQ
01/13Basilea announces approval of antifungal Cresemba(R) (isavuconazole) for invasive asper..
DJ
01/11Basilea Completes Patient Enrolment For New Antibiotic Study
MT
01/11BASILEA PHARMACEUTICA : Updated January 11, 2022
PU
01/11Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigat..
DJ
01/11Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigat..
CI
01/10Basilea Pharmaceutica's Preliminary FY21 Revenue Beats Estimates
MT
01/10BASILEA PHARMACEUTICA : Updated January 10, 2022
PU
01/10Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-positi..
DJ
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 141 M 155 M 155 M
Net income 2021 -22,2 M -24,4 M -24,4 M
Net Debt 2021 82,2 M 90,1 M 90,1 M
P/E ratio 2021 -23,5x
Yield 2021 -
Capitalization 552 M 605 M 605 M
EV / Sales 2021 4,48x
EV / Sales 2022 3,59x
Nbr of Employees 160
Free-Float 87,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 46,56 CHF
Average target price 87,60 CHF
Spread / Average Target 88,1%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG13.78%603
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831